Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy
- PMID: 28677424
- DOI: 10.1177/1010428317701309
Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy
Abstract
The cancer germline antigens MAGE-A1, MAGE-A3, and NY-ESO-1 can be used to target relapsed or therapy-resistant malignant solid tumors, and previous studies have demonstrated that these antigens can be epigenetically upregulated on the surface of tumor cells following exposure to low-dose demethylating chemotherapy agents, such as decitabine. The extent to which cancer germline antigen cytotoxic T lymphocytes can be reliably expanded from healthy donors has not been well characterized, specifically in terms of whether these T cells consistently kill antigen-bearing targets or simply produce interferon-γ in the presence of the antigen. Cancer germline antigen cytotoxic T lymphocytes were generated using conventional method and high-density lymphocyte culture method. We demonstrate that there is no difference in the extent of antigen-specific killing with or without CD25 depletion when interleukin-21 is added to the cultures. Cancer germline antigen-specific killer cells could be expanded from 8/12 healthy donors using overlapping peptide mixes derived from MAGE-A1, MAGE-A3, and NY-ESO-1 and from 7/9 healthy donors using HLA-restricted epitopes. Furthermore, cytotoxic T lymphocyte derived from 4/5 patients displayed specific cytotoxicity of target cells expressing respective cancer germline antigen and HLA partially matched tumor lines. High-density lymphocyte culture prior to stimulation with cancer germline antigen peptides resulted in antigen-specific cytotoxic T lymphocyte from healthy donors and patients from whom cancer germline antigen cytotoxic T lymphocyte culture with conventional methods was not feasible. These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible.
Keywords: Cancer germline antigens; cytotoxic T lymphocytes; high-density pre-culture; immunotherapy.
Similar articles
-
MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.Cancer Immunol Immunother. 2011 Sep;60(9):1299-307. doi: 10.1007/s00262-011-1037-z. Epub 2011 May 28. Cancer Immunol Immunother. 2011. PMID: 21626030 Free PMC article.
-
Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.Int J Cancer. 2007 Jan 15;120(2):337-43. doi: 10.1002/ijc.22309. Int J Cancer. 2007. PMID: 17066423
-
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.Cancer Immunol Immunother. 2015 Oct;64(10):1251-60. doi: 10.1007/s00262-015-1731-3. Epub 2015 Jun 24. Cancer Immunol Immunother. 2015. PMID: 26105625 Free PMC article. Clinical Trial.
-
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.J Clin Pathol. 2001 Sep;54(9):669-74. doi: 10.1136/jcp.54.9.669. J Clin Pathol. 2001. PMID: 11533070 Free PMC article. Review.
-
MAGE-A antigens as targets for cancer immunotherapy.Cancer Treat Rev. 2018 Jun;67:54-62. doi: 10.1016/j.ctrv.2018.04.009. Epub 2018 Apr 26. Cancer Treat Rev. 2018. PMID: 29763778 Review.
Cited by
-
Immunotherapy - The New Era of Oncology.Laryngorhinootologie. 2018 Mar;97(S 01):S3-S47. doi: 10.1055/s-0043-121594. Epub 2018 Mar 22. Laryngorhinootologie. 2018. PMID: 29905353 Free PMC article. Review.
-
Malignant transformation of oral leukoplakia is associated with macrophage polarization.J Transl Med. 2020 Jan 7;18(1):11. doi: 10.1186/s12967-019-02191-0. J Transl Med. 2020. PMID: 31910881 Free PMC article.
-
The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy.Am J Transl Res. 2020 Nov 15;12(11):7002-7019. eCollection 2020. Am J Transl Res. 2020. PMID: 33312347 Free PMC article. Review.
-
Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development.Acta Pharm Sin B. 2021 May;11(5):1083-1097. doi: 10.1016/j.apsb.2020.12.011. Epub 2020 Dec 15. Acta Pharm Sin B. 2021. PMID: 34094821 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials